{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:04:15Z","timestamp":1779109455833,"version":"3.51.4"},"reference-count":164,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roswell Park Alliance Foundation","award":["P30CA16056"],"award-info":[{"award-number":["P30CA16056"]}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30CA16056"],"award-info":[{"award-number":["P30CA16056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Malignant melanoma claims more lives than any other skin malignancy. While primary melanomas are usually cured via surgical excision, the metastatic form of the disease portents a poor prognosis. Decades of intense research has yielded an extensive armamentarium of anti-melanoma therapies, ranging from genotoxic chemo- and radiotherapies to targeted interventions in specific signaling pathways and immune functions. Unfortunately, even the most up-to-date embodiments of these therapies are not curative for the majority of metastatic melanoma patients, and the need to improve their efficacy is widely recognized. Here, we review the reports that implicate p21-regulated kinase 1 (PAK1) and PAK1-related pathways in the response of melanoma to various therapeutic modalities. Ample data suggest that PAK1 may decrease cell sensitivity to programmed cell death, provide additional stimulation to growth-promoting molecular pathways, and contribute to the creation of an immunosuppressive tumor microenvironment. Accordingly, there is mounting evidence that the concomitant inhibition of PAK1 enhances the potency of various anti-melanoma regimens. Overall, the available information suggests that a safe and effective inhibition of PAK1-dependent molecular processes would enhance the potency of the currently available anti-melanoma treatments, although considerable challenges in implementing such strategies still exist.<\/jats:p>","DOI":"10.3390\/cells12192373","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:55:54Z","timestamp":1695880554000},"page":"2373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["PAK1 and Therapy Resistance in Melanoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Julia V.","family":"Kichina","sequence":"first","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St., Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4644-6177","authenticated-orcid":false,"given":"Alexei","family":"Maslov","sequence":"additional","affiliation":[{"name":"Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St., Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-7557","authenticated-orcid":false,"given":"Eugene S.","family":"Kandel","sequence":"additional","affiliation":[{"name":"Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Elm & Carlton St., Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamaophthalmol.2018.1813","article-title":"Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials","volume":"136","author":"Johnson","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Conway, J., Bellet, J.S., Rubin, A.I., and Lipner, S.R. (2023). Adult and Pediatric Nail Unit Melanoma: Epidemiology, Diagnosis, and Treatment. Cells, 12.","DOI":"10.3390\/cells12060964"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0039-6109(02)00187-1","article-title":"Medical management of melanoma","volume":"83","author":"Brown","year":"2003","journal-title":"Surg. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/sonc.2002.35238","article-title":"Metastatic melanoma: Chemotherapy","volume":"29","author":"Bajetta","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108200","DOI":"10.1016\/j.pharmthera.2022.108200","article-title":"The future of targeted kinase inhibitors in melanoma","volume":"239","author":"Caksa","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fernandez, M.F., Choi, J., and Sosman, J. (2023). New Approaches to Targeted Therapy in Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15123224"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: A balance between immunosurveillance and immune escape","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/367040a0","article-title":"A brain serine\/threonine protein kinase activated by Cdc42 and Rac1","volume":"367","author":"Manser","year":"1994","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17171","DOI":"10.1038\/s41598-019-53665-6","article-title":"PAK1, PAK1Delta15, and PAK2: Similarities, differences and mutual interactions","volume":"9","author":"Grebenova","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-017-0744-2","article-title":"JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41388-019-0714-9","article-title":"Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients","volume":"38","author":"Chu","year":"2019","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2008.01.008","article-title":"miRNAs: Little known mediators of oncogenesis","volume":"18","author":"Gartel","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1152\/physiol.00139.2005","article-title":"Ste20-type kinases: Evolutionarily conserved regulators of ion transport and cell volume","volume":"21","author":"Strange","year":"2006","journal-title":"Physiology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/14728222.2010.492779","article-title":"PAK1 as a therapeutic target","volume":"14","author":"Kichina","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0092-8674(00)00043-X","article-title":"Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch","volume":"102","author":"Lei","year":"2000","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2010.10.015","article-title":"Phosphoinositides are essential coactivators for p21-activated kinase 1","volume":"40","author":"Strochlic","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Eid, S., Turk, S., Volkamer, A., Rippmann, F., and Fulle, S. (2017). KinMap: A web-based tool for interactive navigation through human kinome data. BMC Bioinform., 18.","DOI":"10.1186\/s12859-016-1433-7"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.7618083","article-title":"Regulation of human leukocyte p21-activated kinases through G protein\u2014coupled receptors","volume":"269","author":"Knaus","year":"1995","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jmb.2006.06.017","article-title":"A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases","volume":"361","author":"Pirruccello","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.str.2011.10.013","article-title":"Structural insights into the autoactivation mechanism of p21-activated protein kinase","volume":"19","author":"Wang","year":"2011","journal-title":"Structure"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1021\/bi980140+","article-title":"Delineation of the Cdc42\/Rac-binding domain of p21-activated kinase","volume":"37","author":"Thompson","year":"1998","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1074\/jbc.273.14.8137","article-title":"A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids","volume":"273","author":"Bokoch","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2016.12.014","article-title":"Structure, biochemistry, and biology of PAK kinases","volume":"605","author":"Kumar","year":"2017","journal-title":"Gene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","article-title":"P21 activated kinase signaling in cancer","volume":"54","author":"Rane","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9741","DOI":"10.7150\/thno.46913","article-title":"P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer","volume":"10","author":"Yao","year":"2020","journal-title":"Theranostics"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Somanath, P.R., Chernoff, J., Cummings, B.S., Prasad, S.M., and Homan, H.D. (2023). Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15082236"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/mc.22611","article-title":"P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells","volume":"56","author":"Babagana","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.cmr.0000222589.30117.f2","article-title":"Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma","volume":"16","author":"Pavey","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/djt054","article-title":"P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma","volume":"105","author":"Ong","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13073-022-01068-0","article-title":"Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.6004\/jnccn.2014.0172","article-title":"Analysis of recurrence patterns in acral versus nonacral melanoma: Should histologic subtype influence treatment guidelines?","volume":"12","author":"Gumaste","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1158\/0008-5472.CAN-12-2246","article-title":"p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model","volume":"72","author":"Chow","year":"2012","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4161\/cc.3.1.593","article-title":"PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition","volume":"3","author":"Nheu","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.19.3.1881","article-title":"Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts","volume":"19","author":"Tang","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/374457a0","article-title":"An essential role for Rac in Ras transformation","volume":"374","author":"Qiu","year":"1995","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Vanni, I., Tanda, E.T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., and Ghiorzo, P. (2020). Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00172"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"key":"ref_55","first-page":"E1296","article-title":"Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma","volume":"113","author":"Shi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2008-04-155085","article-title":"Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+\/- mast cells","volume":"112","author":"McDaniel","year":"2008","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.009","article-title":"Characterisation and outcome of RAC1 mutated melanoma","volume":"183","author":"Lodde","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.molcel.2012.10.018","article-title":"A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors","volume":"49","author":"Vaque","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2018.01.081","article-title":"GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma","volume":"22","author":"Moore","year":"2018","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1530\/ERC-14-0424","article-title":"BRAF activates and physically interacts with PAK to regulate cell motility","volume":"21","author":"McCarty","year":"2014","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_63","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview","volume":"19","author":"Serrone","year":"2000","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16","volume":"108","author":"Melia","year":"2001","journal-title":"Ophthalmology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13014-020-01615-2","article-title":"Radiotherapy for lentigo maligna and lentigo maligna melanoma\u2014A systematic review","volume":"15","author":"Hendrickx","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-319-22539-5_13","article-title":"Mucosal Melanoma: Epidemiology, Biology and Treatment","volume":"167","author":"Spencer","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jso.23509","article-title":"Radiation therapy for advanced and metastatic melanoma","volume":"109","author":"Fogarty","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/15384101.2022.2131163","article-title":"Radiation-induced liver disease: Beyond DNA damage","volume":"22","author":"Zhou","year":"2023","journal-title":"Cell Cycle"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"31119","DOI":"10.1074\/jbc.274.44.31119","article-title":"p21-activated protein kinase gamma-PAK is activated by ionizing radiation and other DNA-damaging agents. Similarities and differences to alpha-PAK","volume":"274","author":"Roig","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.dnarep.2018.03.004","article-title":"p21 Activated kinase 1: Nuclear activity and its role during DNA damage repair","volume":"65","year":"2018","journal-title":"DNA Repair"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Motwani, M., Li, D.Q., Horvath, A., and Kumar, R. (2013). Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066585"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-12-0775","article-title":"RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage","volume":"72","author":"Ho","year":"2012","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2004.05.022","article-title":"Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes","volume":"5","author":"Vadlamudi","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/MCB.20.2.453-461.2000","article-title":"p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis","volume":"20","author":"Schurmann","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"24698","DOI":"10.1074\/jbc.M413374200","article-title":"p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association","volume":"280","author":"Jin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(02)03846-2","article-title":"Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells","volume":"535","author":"Mazumdar","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"19693","DOI":"10.1074\/jbc.M909860199","article-title":"Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1","volume":"275","author":"Frost","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1073\/pnas.0502463102","article-title":"Mutagenesis by reversible promoter insertion to study the activation of NF-kappaB","volume":"102","author":"Kandel","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Huang, C., Radi, R.H., and Arbiser, J.L. (2021). Mitochondrial Metabolism in Melanoma. Cells, 10.","DOI":"10.3390\/cells10113197"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Dillon, M., Lopez, A., Lin, E., Sales, D., Perets, R., and Jain, P. (2021). Progress on Ras\/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13205059"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"36609","DOI":"10.1074\/jbc.M502306200","article-title":"Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors","volume":"280","author":"Beeser","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/MCB.16.7.3707","article-title":"Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members","volume":"16","author":"Frost","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"16244","DOI":"10.1074\/jbc.M501185200","article-title":"B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms","volume":"280","author":"Tran","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/MCB.22.17.6023-6033.2002","article-title":"Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes","volume":"22","author":"Eblen","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1541-7786.MCR-20-0839","article-title":"Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma","volume":"19","author":"Broit","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Wr\u00f3blewska, J.P., Dias-Santagata, D., Ustaszewski, A., Wu, C.L., Fujimoto, M., Selim, M.A., Biernat, W., Ry\u015b, J., Marszalek, A., and Hoang, M.P. (2021). Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. Cells, 10.","DOI":"10.3390\/cells10092216"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lebbe, C., Dutriaux, C., Lesimple, T., Kruit, W., Kerger, J., Thomas, L., Guillot, B., Braud, F., Garbe, C., and Grob, J.J. (2020). Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, 12.","DOI":"10.3390\/cancers12071727"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"975643","DOI":"10.3389\/fonc.2022.975643","article-title":"Intermittent MEK inhibition for the treatment of metastatic uveal melanoma","volume":"12","author":"Khan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1073\/pnas.1418163112","article-title":"BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model","volume":"112","author":"Perna","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1158\/0008-5472.CAN-09-4471","article-title":"Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells","volume":"70","author":"Shao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/excr.1999.4690","article-title":"The regulation and activities of the multifunctional serine\/threonine kinase Akt\/PKB","volume":"253","author":"Kandel","year":"1999","journal-title":"Exp. Cell Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1101\/gad.889901","article-title":"Inhibition of early apoptotic events by Akt\/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase","volume":"15","author":"Gottlob","year":"2001","journal-title":"Genes Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1128\/MCB.22.22.7831-7841.2002","article-title":"Activation of Akt\/protein kinase B overcomes a G(2)\/m cell cycle checkpoint induced by DNA damage","volume":"22","author":"Kandel","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1128\/MCB.19.8.5800","article-title":"Akt\/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria","volume":"19","author":"Kennedy","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","article-title":"AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma","volume":"37","author":"Zuo","year":"2018","journal-title":"Oncogene"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mc.23123","article-title":"The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies","volume":"59","author":"Babagana","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1369-5274(00)00143-0","article-title":"Pheromone response, mating and cell biology","volume":"3","author":"Elion","year":"2000","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/onc.2009.114","article-title":"The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt","volume":"28","author":"Somanath","year":"2009","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1074\/jbc.275.13.9106","article-title":"The Akt proto-oncogene links Ras to Pak and cell survival signals","volume":"275","author":"Tang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"700","DOI":"10.18632\/oncotarget.587","article-title":"The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes","volume":"3","author":"Singhal","year":"2012","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","article-title":"The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF","volume":"74","author":"Watson","year":"2014","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ruiz, R., Jahid, S., Harris, M., Marzese, D.M., Espitia, F., Vasudeva, P., Chen, C.F., de Feraudy, S., Wu, J., and Gillen, D.L. (2017). The RhoJ-BAD signaling network: An Achilles\u2019 heel for BRAF mutant melanomas. PLoS Genet., 13.","DOI":"10.1371\/journal.pgen.1006913"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/onc.2017.400","article-title":"Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors","volume":"37","author":"Feng","year":"2018","journal-title":"Oncogene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/noac212","article-title":"A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells","volume":"25","author":"Gimotty","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/jnci\/djt075","article-title":"Taming the wild-types: Targeting PAK1 in melanomas that lack BRAF mutations","volume":"105","author":"Smalley","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/(SICI)1097-0215(19971114)73:4<470::AID-IJC3>3.0.CO;2-X","article-title":"Melanomas that develop within the eye inhibit lymphocyte proliferation","volume":"73","author":"Verbik","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Babagana, M., Brown, L.R., Slabodkin, H.Z., Kichina, J.V., and Kandel, E.S. (2021). Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKT. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111376"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1074\/jbc.M200083200","article-title":"Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization","volume":"277","author":"Kissil","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1097-2765(03)00382-4","article-title":"Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1","volume":"12","author":"Kissil","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1074\/jbc.C100553200","article-title":"p21-activated kinase links Rac\/Cdc42 signaling to merlin","volume":"277","author":"Xiao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"19179","DOI":"10.1074\/jbc.M117.808063","article-title":"beta1 integrin-dependent Rac\/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2\/merlin","volume":"292","author":"Sabra","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chocarro, L., Bocanegra, A., Blanco, E., Fern\u00e1ndez-Rubio, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Pi\u00f1eiro-Hermida, S., and Vera, R. (2022). Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells, 11.","DOI":"10.3390\/cells11152351"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Damato, B.E., Dukes, J., Goodall, H., and Carvajal, R.D. (2019). Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11070971"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Huynh, N., Wang, K., Yim, M., Dumesny, C.J., Sandrin, M.S., Baldwin, G.S., Nikfarjam, M., and He, H. (2017). Depletion of p21-activated kinase 1 up-regulates the immune system of APC(\u220614\/+) mice and inhibits intestinal tumorigenesis. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3432-0"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/cas.12503","article-title":"Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-gamma treatment","volume":"105","author":"Mimura","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e22890","DOI":"10.4161\/onci.22890","article-title":"Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells","volume":"2","author":"Sapkota","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2326-6066.CIR-20-0905","article-title":"Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity","volume":"9","author":"Phadke","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41467-019-14224-9","article-title":"Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS(G13D)","volume":"11","author":"Kennedy","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12392","article-title":"RAC1 P29S regulates PD-L1 expression in melanoma","volume":"28","author":"Vu","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.020","article-title":"Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.274.5291.1363","article-title":"Melanoma cell expression of Fas(Apo-1\/CD95) ligand: Implications for tumor immune escape","volume":"274","author":"Hahne","year":"1996","journal-title":"Science"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20011624","article-title":"Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles","volume":"195","author":"Andreola","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_140","first-page":"59","article-title":"Human melanoma cells do not express Fas (Apo-1\/CD95) ligand","volume":"59","author":"Chappell","year":"1999","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.4049\/jimmunol.179.10.6384","article-title":"Cutting edge: Rac GTPases sensitize activated T cells to die via Fas","volume":"179","author":"Ramaswamy","year":"2007","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Yarchoan, M., Mohan, A.A., Dennison, L., Vithayathil, T., Ruggieri, A., Lesinski, G.B., Armstrong, T.D., Azad, N.S., and Jaffee, E.M. (2019). MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224600"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BST20160134","article-title":"Targeting PAK1","volume":"45","author":"Semenova","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2008-06-160861","article-title":"p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics","volume":"113","author":"Allen","year":"2009","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/cl.21497","article-title":"Novel roles of PAK1 in the heart","volume":"2","author":"Ke","year":"2012","journal-title":"Cell. Logist."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/15384101.2019.1578149","article-title":"The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditions","volume":"18","author":"Zynda","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00335-011-9326-6","article-title":"Functional PAK-2 knockout and replacement with a caspase cleavage-deficient mutant in mice reveals differential requirements of full-length PAK-2 and caspase-activated PAK-2p34","volume":"22","author":"Marlin","year":"2011","journal-title":"Mamm. Genome"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1242\/jcs.01392","article-title":"The genetics of Pak","volume":"117","author":"Hofmann","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1523\/JNEUROSCI.0028-05.2005","article-title":"Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3","volume":"25","author":"Meng","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"15627","DOI":"10.1021\/acs.jmedchem.2c00756","article-title":"Development and Utility of a PAK1-Selective Degrader","volume":"65","author":"Chow","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1021\/acsmedchemlett.5b00102","article-title":"Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor","volume":"6","author":"Karpov","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"707317","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Thompson, Z.J., Teer, J.K., Li, J., Chen, Z., Welsh, E.A., Zhang, Y., Ayoubi, N., Eroglu, Z., Tan, A.C., and Smalley, K.S.M. (2022). Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment. Cells, 11.","DOI":"10.3390\/cells11182894"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.chembiol.2008.03.005","article-title":"An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase","volume":"15","author":"Deacon","year":"2008","journal-title":"Chem. Biol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/jm501613q","article-title":"Inhibitors of p21-activated kinases (PAKs)","volume":"58","author":"Rudolph","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.nano.2016.01.003","article-title":"Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo","volume":"12","author":"Missaoui","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui, W., Quach, N.D., Somanath, P.R., and Cummings, B.S. (2020). Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A(2) (sPLA(2)) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249396"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Bailly, C., Beignet, J., Loirand, G., and Sauzeau, V. (2022). Rac1 as a therapeutic anticancer target: Promises and limitations. Biochem. Pharmacol., 203.","DOI":"10.1016\/j.bcp.2022.115180"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Mosaddeghzadeh, N., and Ahmadian, M.R. (2021). The RHO Family GTPases: Mechanisms of Regulation and Signaling. Cells, 10.","DOI":"10.3390\/cells10071831"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1038\/s41467-021-26324-6","article-title":"Regulation of local GTP availability controls RAC1 activity and cell invasion","volume":"12","author":"Wolff","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2008.11.003","article-title":"Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis","volume":"14","author":"Nogueira","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/15384101.2021.1922806","article-title":"Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma","volume":"20","author":"Barnaba","year":"2021","journal-title":"Cell Cycle"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Maresca, L., Stecca, B., and Carrassa, L. (2022). Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells, 11.","DOI":"10.3390\/cells11091466"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/19\/2373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:25Z","timestamp":1760130025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/19\/2373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":164,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cells12192373"],"URL":"https:\/\/doi.org\/10.3390\/cells12192373","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}